Management of venous thromboembolism in pregnancy.
Anticoagulants
Deep venous thrombosis
Pregnancy
Pulmonary embolism
Venous thromboembolism
Journal
Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
25
10
2021
revised:
17
01
2022
accepted:
02
02
2022
pubmed:
13
2
2022
medline:
1
4
2022
entrez:
12
2
2022
Statut:
ppublish
Résumé
Venous thromboembolism (VTE) in pregnancy, consisting of deep venous thrombosis (DVT) and pulmonary embolism (PE), is a major factor of maternal mortality. Several patient-specific risk factors along with the physiologic changes of pregnancy promote a state of hypercoagulability in pregnant women. Detailed assessment of all pregnant women can establish a risk profile that would guide clinical decisions, and balance potential therapeutic benefits with side effects. Differentiating between physiologic changes of pregnancy and symptoms of VTE can be challenging and warrants meticulous clinical evaluation. Timely and accurate diagnosis of VTE with proper imaging is essential for its management, and systemic anticoagulation remains the cornerstone of VTE prevention and therapy. Furthermore, advanced invasive treatment options such as inferior vena cava filters and thrombectomy can be considered for complex cases. Importantly, the risk of systemic anticoagulation should be balanced against the risk of VTE-associated morbidity and mortality for mother and fetus, and an informed decision should be made. In this review, we present an up-to-date overview of VTE management in pregnancy and the postpartum period.
Identifiants
pubmed: 35149395
pii: S0049-3848(22)00040-8
doi: 10.1016/j.thromres.2022.02.002
pii:
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
106-113Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.